Comparative Pharmacology
Head-to-head clinical analysis: GADOTERATE MEGLUMINE versus MAGNEVIST.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GADOTERATE MEGLUMINE versus MAGNEVIST.
GADOTERATE MEGLUMINE vs MAGNEVIST
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Gadoterate meglumine is a paramagnetic contrast agent that increases the relaxation rate of water protons in tissues, thereby enhancing image contrast in magnetic resonance imaging (MRI). It is a macrocyclic gadolinium-based contrast agent (GBCA) with high thermodynamic stability and kinetic inertness, reducing the risk of gadolinium dissociation.
Gadopentetate dimeglumine is a paramagnetic contrast agent that shortens T1 and T2 relaxation times in tissues where it accumulates, enhancing signal intensity on T1-weighted magnetic resonance imaging (MRI). It distributes extracellularly and does not cross the intact blood-brain barrier, but accumulates in areas of disrupted barrier or abnormal vascularity.
0.2 mL/kg (0.1 mmol/kg) intravenously as a single bolus injection.
0.2 mL/kg (0.1 mmol/kg) intravenously, up to 0.6 mL/kg (0.3 mmol/kg) for certain indications, with a maximum of 20 mL per dose.
None Documented
None Documented
Terminal elimination half-life approximately 1.5–2 hours in patients with normal renal function; prolonged in renal impairment (up to 12–34 hours in severe impairment).
Terminal elimination half-life in patients with normal renal function is approximately 1.6 hours. In patients with impaired renal function, half-life is prolonged (up to 30 hours with GFR <30 mL/min).
Primarily renal (99% excreted unchanged in urine within 24 hours); biliary/fecal elimination negligible (<1%).
Renal excretion of unchanged gadopentetate dimeglumine accounts for approximately 99% of the administered dose within 72 hours. Biliary/fecal excretion is negligible (<0.5%).
Category C
Category C
Contrast Agent
Contrast Agent